Connect
MJA
MJA

Botulinum toxin type A should be PBS listed for treatment of palmar hyperhidrosis

Ingrid C Chung and Bruce C L McGeorge
Med J Aust 2012; 197 (8): . || doi: 10.5694/mja12.11150
Published online: 15 October 2012

To the Editor: Hyperhidrosis is uncontrollable, excessive sweating. Severe primary focal palmar hyperhidrosis is a significant disability. It interferes with many activities of daily living and induces social avoidance behaviours that can lead to symptoms of social anxiety disorder. Symptoms begin in childhood or around puberty and affect both sexes equally.1


  • 1 Royal Darwin Hospital, Darwin, NT.
  • 2 Faculty of Health Sciences, Flinders University, Adelaide, SA.


Correspondence: Ingrid.Chung@nt.gov.au

Competing interests:

No relevant disclosures.

  • 1. Fealey RD, Hebert AA. Disorders of the eccrine sweat glands and sweating. In: Goldsmith LA, Katz SI, Gilchrest BA, et al, editors. Fitzpatrick’s dermatology in general medicine. 8th ed. New York: McGraw-Hill, 2012: 936-946.
  • 2. Bhidayasiri R, Truong D. Expanding use of botulinum toxin. J Neurol Sci 2005; 235: 1-9.
  • 3. Shelley WB, Talanin NY, Shelley ED. Botulinum toxin therapy for palmar hyperhidrosis. J Am Acad Dermatol 1998; 38: 227-229.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.